StockData
AbbVie Inc. logo

AbbVie Inc. (ABBV) operating KPIs

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026Score 10/3094% above fair value
$294.89+4.10 (+1.41%)

Close on Oct 30, 2026Market cap $521.11BP/E 83.3Yield 2.26%

AbbVie immunology Portfolio — U.S. net revenues ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Key Product Revenues

QuarterlyAnnual
Latest, Q2 2026
6,957
Period ended Jun 30, 2026
Change on a year earlier
+14.1%
6,097 in Q2 2025
History
32 quarters
Since Q3 2018
Sources
32
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedImmunology Portfolio — U.S. net revenues ($M) ($M)Year on yearSource
Q2 2026Jun 30, 20266,957+14.1%Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 20265,537+13.4%Form 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20256,961+17.9%Form 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 20256,263+9.6%Form 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20256,097+6.6%Form 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 20254,883+17.6%Form 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 20245,905+2.3%Form 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 20245,713+0.3%Form 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 20245,717-0.2%Form 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 20244,152-8.5%Form 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 20235,774-17.2%Form 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 20235,696-14.8%Form 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 20235,731-6.9%Form 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 20234,536-10.8%Form 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 20226,975+22.5%Form 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 20226,682+18.5%Form 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Breakdown

What makes up immunology portfolio — u.s. net revenues ($m)

Cite this data

StockData. (2026). AbbVie Immunology Portfolio — U.S. net revenues ($M) ($M), quarterly Q3 2018–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/ta_imm_us

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.